CARDENE
LOE ApproachingNDAORALCAPSULE
Approved
Dec 1988
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
CARDENE by Chiesi is concentrations. Approved for not desirable. First approved in 1988.
Drug data last refreshed 14h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CARDENE (nicardipine) is an oral calcium channel blocker approved in 1988 that selectively relaxes vascular smooth muscle to treat hypertension and angina. It works by inhibiting calcium ion influx into cardiac and vascular smooth muscle cells, with preferential effects on coronary vasculature. The drug is administered as an oral capsule and has demonstrated minimal negative inotropic effects in animal models.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), indicating potential team contraction and shift toward cost management rather than growth initiatives.
Mechanism of Action
concentrations. The contractile processes of cardiac muscle and vascular smooth muscle are dependent upon the movement of extracellular calcium ions into these cells through specific ion channels. The effects of nicardipine are more selective to vascular smooth muscle than cardiac muscle. In animal…
Indications (1)
Career Relevance
Working on CARDENE offers limited career growth opportunities given its LOE-approaching status and lack of linked job openings. Roles available are primarily defensive in nature, focused on market maintenance, competitive monitoring, and generic transition planning rather than innovation or expansion.
Worked on CARDENE at Chiesi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.